Background-Merkel cell carcinoma (MCC) is an aggressive skin cancer with a mortality of 33%. Advanced disease at diagnosis is a poor prognostic factor, suggesting that earlier detection may improve outcome. No systematic analysis has been published to define the clinical features that are characteristic of MCC.
Introduction
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with a mortality of approximately 33% at 3 years 1 , higher than that of melanoma (approximately 15%). Data from Surveillance, Epidemiology, and End Results (SEER) show a three-fold increase in MCC from 0.15 to 0.44 per 100,000 annually from the years 1986 to 2001 2 . This trend is continuing, and approximately 1000-1500 new cases will be diagnosed in the United States in 2007 3, 4 . Several factors likely contribute to this including an aging population, increased aggregate sun exposure and a higher number of immune suppressed individuals. Furthermore, the advent of the immunohistochemical marker cytokeratin-20 (CK-20) improved recognition of this disease. In the era before widespread CK-20 immunohistochemistry, laborious electron microscopy was required to make an accurate MCC diagnosis. Indeed, 66% of MCC cases in one series would have been misdiagnosed (as metastatic small cell lung cancer, basal cell carcinoma, lymphoma or other metastatic carcinoma) if electron microscopy had not been performed demonstrating the characteristic "neurosecretory granules within cytoplasmic extensions" 5 .
Management of MCC is controversial. To date there have been no controlled therapeutic trials in this disease. In most cases, surgical excision with sentinel lymph node biopsy 1, 6 followed by radiation 7, 8 is indicated. Conventional adjuvant chemotherapy lacks evidence of survival benefit and may in fact be associated with poorer outcomes 1, 9 . A consensus treatment algorithm has been developed by the National Comprehensive Cancer Network 10 .
MCC prognosis is highly associated with the extent of disease at presentation. Disease-specific survival rates for local disease are greater than 90%, falling to 52% with nodal involvement 3 . If distant metastatic disease is present, expected survival is typically less than 10% at three years 1 . As delay in diagnosis could allow disease progression, early detection and clinician recognition of this disease may improve survival rates. At present, a detailed description of the clinical characteristics of MCC at the time of diagnosis has not been published. Specifically, a PubMed search of "Merkel cell carcinoma clinical features" (performed on 10/24/07) yielded 87 studies, none of which described the clinician's presumptive diagnosis, the color or symptomatic nature of the lesion, or the time to biopsy after lesion appearance.
The purpose of this study is to identify key clinical features that may assist the clinician in recognizing this aggressive skin cancer at an earlier and potentially more curable point. 
Patients and Methods

Results
Patient characteristics
As shown in Table I , the median age at diagnosis was 69 years, with 90% of patients being over age 50. There was a slight male predominance with a ratio of 1.4:1 (58.5% males and 41.5% females). The vast majority of patients were Caucasian (98%), with only 4 patients being non-white (3 Asian and 1 Black). Profound immunosuppression including HIV (3 patients), CLL (8 patients) or solid organ transplant (4 patients) was noted in 7.8% of patients. The mean age of presentation of the immunosuppressed patients in this series was comparable to that of the immunocompetent group, 65 vs. 67 years respectively.
One hundred and six patients (57%) presented with local disease. Seventy patients (37%) presented with nodal disease; of these, 27 (14% of the total patients) had nodal presentation with no identified primary. Eleven patients (6%) presented with metastatic disease. Information regarding the time from lesion appearance to biopsy was available in 144 patients with a primary lesion. The median time to biopsy was 3 months (mean 5.3 months, range 1-54 months).
Tumor characteristics
Examples of MCC presentation which include lesions that initially were thought to be a cyst or other benign process are shown in Figure I . As outlined in Table II , the diameter of the primary tumor was <1 cm in 32 patients (21.3%), 1-2cm in 65 patients (43.3%) and >2 cm in 53 patients (35.3%). The most common color of the primary lesion was red/pink, seen in 56% of patients, followed by blue/violaceous noted in 26%. Most (88%) of the lesions were asymptomatic. Sixty-three percent of patients reported rapid growth of their tumor within 3 months. Only a minority (11%) reported no changes in the size of their primary lesion. Figure II shows the distribution of primary MCC tumors as well as those that presented in the lymph node without a known primary. Most lesions appeared on sun-exposed skin; however, 19% presented on the buttock or other minimally sun-exposed areas. The most common anatomic site of the primary lesion was the head and neck (29%), followed by the lower limbs (24%) and upper extremities (21%). Nodal disease in the setting of no identified primary tumor was diagnosed in 27 patients (14%). (Table III) Among the group of 106 patients for whom a presumed clinical diagnosis was reported, the majority (56%) of clinical impressions were benign (Table IV) . A cyst or acneiform lesion was the single most common presumptive diagnosis (32%), followed by lipoma (6%), dermatofibroma or fibroma (4%) and vascular lesion (4%). Malignant diagnoses comprised an additional 36% of the clinical impressions, with non-melanoma skin cancer being the most common of these (19%), followed by lymphoma (6%), metastatic carcinoma (2%) and sarcoma (2%). The correct clinical diagnosis of MCC was made presumptively in only two cases (1%).
The five most common clinical features were used to create an acronym: AEIOU (Asymptomatic/lack of tenderness, Expanding rapidly ( ≤ 3 months), Immunosuppression, Older than age 50, and location on a UV-exposed site (Table V) ). All five of these data points were known in 62 patients. Eighty-nine percent of patients met 3 or more criteria, 52% met 4 or more criteria and 7% met all 5 criteria.
Discussion
This study of 195 patients was conducted to identify key features of MCC that may aid clinicians in recognizing when a biopsy may be warranted. The basic demographic profile of our cohort is similar to that described in other studies: mostly elderly, Caucasian and with a slight male predominance.
The anatomic distribution of the tumors seen in our study further supports sun-exposure as a risk factor for the development of MCC, consistent with prior studies. Agelli et al. used SEER Registry data to demonstrate a positive association between geographic UV-B radiation indices and age-adjusted MCC incidence among White patients in a variety of US cities 3 . In patients receiving PUVA (psoralen + UV-A) for psoriasis, Lunder and Stern reported the incidence of MCC to be approximately 100 times that expected in the general population 14 . In our series, 81% of cases presented on UV-exposed skin. While sun exposure is strongly associated with MCC, as in melanoma, MCC can arise in the absence of significant UV exposure. Importantly, 5% of patients had tumors on highly sun-protected sites (buttock or vulva), and 14% had tumors arise on partially protected sites (abdomen, thighs and hair-bearing scalp).
Profound immunosuppression also appears to be an important risk factor for MCC. Indeed, 7.8% of our patients had some form of immunosuppression, including HIV, CLL, or iatrogenic suppression secondary to solid organ transplantation. This frequency is a 16-fold overrepresentation of that expected in the general US population, in which the estimated prevalences are 0.4% for HIV 15 , 0.029% for CLL 11, 12 , and 0.075% 12, 13 for solid organ transplantation. Among our immunosuppressed patients, CLL was particularly over-represented (4.1%). The age-adjusted incidence of CLL in our cohort was 2.4% for 50-69 year olds and and 6.5% for ≤ 70 year olds, representing a respective 48-fold and 34-fold increase above that expected in the US population for those age groups. MCC arising in the setting of CLL has been described 19-23 , but to the best of our knowledge, this is the first quantitation of the degree to which MCC is over-represented in this disease. We acknowledge the potential for referral bias in our series because immune suppressed patients may be more likely to be seen in tertiary medical centers. However, in 3 of the 15 cases, MCC was diagnosed first, and the immune suppressed state (HIV or CLL) was discovered as part of the MCC workup. This finding also supports the need for practitioners to consider further workup for immunosuppression in patients presenting with MCC.
In agreement with a prior study of transplant patients, we observed more advanced disease at time of presentation in the immunosuppressed group; ten of the fifteen (67%) immunocompromised patients presented with either nodal or distant metastatic disease as compared to 42% in the immunocompetent group (difference not statistically significant). In contrast to reports of organ transplant recipients and HIV positive patients developing MCC at an earlier age 17, 24, 25 , we did not find a difference in the mean ages of immunosuppressed and immunocompetent MCC patients. This likely reflects the inclusion of 8 patients with CLL, a disease with a mean age of 65.
Clinicians thought most lesions were benign prior to biopsy, which may have contributed to a delay in the diagnosis. Although not quantified, many of our patients reported they had been reassured by a physician about the benign nature of their lesion. Indeed, several of the characteristic MCC features were present at that earlier visit. It is hoped that publicizing the clinical characteristics of MCC may result in an earlier diagnosis in some cases.
We identified several tumor characteristics that may aid a clinician in suspecting MCC, summarized as AEIOU (Table V) . Of particular note, we consider lack of tenderness an important feature in MCC as many other lesions that are rapidly growing and red or pink (such as an inflamed cyst, the most common presumed diagnosis) would likely be tender.
Here we describe the first systematic analysis of the clinical features of Merkel cell carcinoma. We have identified several characteristics that in combination are highly sensitive for the diagnosis of MCC. While we do not have data to address the specificity of these features, it is likely to be low given the rarity of MCC. Among lesions encountered in routine clinical practice that display multiple of these features, only a few may be MCC while others, such as squamous cell carcinoma or keratoacanthoma, would also have required a biopsy. Thus, the use of these criteria to aid in the decision to perform a biopsy may be appropriate. Given the correlation between survival and stage at presentation 1 , identifying patients at an earlier and potentially more curable point is highly desirable for Merkel cell carcinoma. A. An eyelid lesion that was thought to be a rapidly growing chalazion. B. A non-tender MCC that arose on the buttock of a patient with HIV. The MCC diagnosis was markedly delayed because of a history of multiple prior epidermoid cysts. C. A finger lesion that was clinically suggestive of a pyogenic granuloma or amelanotic melanoma. D. A MCC that arose on a sun-exposed area of the arm in a man with fair skin (photo courtesy of http://www.merkelcell.co.uk, used with permission).
Figure II. Distribution of MCC at Presentation in 195 Patients
A primary skin lesion (solid circle •) was seen in 168 patients (86%). Twenty-seven (14%) presented with nodal involvement and no known primary (open circles ○). 
